A number of other equities analysts also recently issued reports on the stock. Argus downgraded shares of Regeneron Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, June 18th. Piper Jaffray Companies reiterated an overweight rating and issued a $435.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, May 7th. BMO Capital Markets downgraded shares of Capital Power from an outperform rating to a market perform rating in a report on Wednesday, May 8th. Citigroup downgraded shares of Barrick Gold to a neutral rating in a report on Thursday, May 23rd. Finally, Morgan Stanley reiterated an overweight rating and issued a GBX 2,280 ($29.79) price target on shares of Anglo American in a report on Wednesday, May 8th. Three analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of Hold and a consensus target price of $395.78.
REGN stock opened at $298.20 on Friday. Regeneron Pharmaceuticals has a one year low of $287.66 and a one year high of $442.00. The firm has a market cap of $31.84 billion, a PE ratio of 15.06, a PEG ratio of 1.37 and a beta of 1.11. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.58 and a quick ratio of 3.78. The stock has a fifty day moving average price of $307.35.
In other Regeneron Pharmaceuticals news, EVP Neil Stahl sold 9,853 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $305.74, for a total transaction of $3,012,456.22. Following the completion of the transaction, the executive vice president now directly owns 47,450 shares in the company, valued at approximately $14,507,363. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $305.93, for a total transaction of $305,930.00. Following the transaction, the director now owns 11,323 shares of the company’s stock, valued at $3,464,045.39. The disclosure for this sale can be found here. Company insiders own 11.84% of the company’s stock.
Large investors have recently bought and sold shares of the business. Capital Financial Planning LLC purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $33,000. Landsberg Bennett & Dubbaneh LLC grew its holdings in shares of Regeneron Pharmaceuticals by 13.5% during the first quarter. Landsberg Bennett & Dubbaneh LLC now owns 815 shares of the biopharmaceutical company’s stock worth $332,000 after buying an additional 97 shares in the last quarter. Schaper Benz & Wise Investment Counsel Inc. WI grew its holdings in shares of Regeneron Pharmaceuticals by 1.3% during the first quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 16,826 shares of the biopharmaceutical company’s stock worth $6,909,000 after buying an additional 216 shares in the last quarter. Sontag Advisory LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $68,000. Finally, Intellectus Partners LLC grew its holdings in shares of Regeneron Pharmaceuticals by 83.6% during the fourth quarter. Intellectus Partners LLC now owns 2,477 shares of the biopharmaceutical company’s stock worth $925,000 after buying an additional 1,128 shares in the last quarter. Hedge funds and other institutional investors own 66.86% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Article: Do Tariffs Work?
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.